AstraZeneca Pharma India Limited has officially confirmed its compliance with security dematerialization protocols for the period ending March 31, 2026. The company, in coordination with its Registrar and Transfer Agents, verified that all security certificates received from participants were processed, mutilated, and cancelled within the mandated 15-day timeframe, with the depository successfully substituted as the registered owner in corporate records.
Processing of Securities
Following the standard procedures for share dematerialization, the company has completed its verification for the period of March 1, 2026, to March 31, 2026. All certificate-based securities received by the company’s registrar, Integrated Registry Management Services Private Limited, were processed in accordance with established standards to facilitate electronic holdings.
Compliance and Verification
The company maintains a rigorous oversight process to ensure that all share certificates received for conversion into dematerialized form are properly mutilated and cancelled upon processing. Furthermore, the records of the company have been updated to reflect the depository as the official registered owner of these securities. This process ensures that all dematerialized shares remain listed on the relevant stock exchanges, providing liquidity and transparency for shareholders.
Source: BSE
